Compare MAN & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MAN | URGN |
|---|---|---|
| Founded | 1948 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.2B |
| IPO Year | 1994 | 2016 |
| Metric | MAN | URGN |
|---|---|---|
| Price | $46.07 | $26.27 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 12 | 7 |
| Target Price | $51.94 | ★ $60.71 |
| AVG Volume (30 Days) | 911.0K | ★ 1.2M |
| Earning Date | 10-15-2026 | 11-04-2026 |
| Dividend Yield | ★ 3.12% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.89 | N/A |
| Revenue | ★ $17,957,100,000.00 | $1,128,000.00 |
| Revenue This Year | $6.51 | $190.44 |
| Revenue Next Year | $3.29 | $69.25 |
| P/E Ratio | $24.28 | ★ N/A |
| Revenue Growth | ★ 0.58 | N/A |
| 52 Week Low | $25.15 | $16.50 |
| 52 Week High | $63.88 | $50.81 |
| Indicator | MAN | URGN |
|---|---|---|
| Relative Strength Index (RSI) | 44.18 | 29.46 |
| Support Level | $25.57 | $22.61 |
| Resistance Level | $48.48 | $27.76 |
| Average True Range (ATR) | 1.67 | 2.03 |
| MACD | 0.40 | -0.45 |
| Stochastic Oscillator | 47.54 | 20.19 |
ManpowerGroup Inc provides workforce solutions and services, including recruitment and assessment, upskilling, reskilling, training and development, career management, outsourcing, and workforce consulting. The company leverages its trusted brands, industry knowledge, and AI-enabled assessments and offers an extensive portfolio of training and leadership development solutions. Its reportable segments are Staffing and Interim, Outcome-Based Solutions and Consulting, Permanent Recruitment, and Others, with Staffing and Interim generating the majority of revenue. It operates in the Americas, Southern Europe, Northern Europe, and APME. The company derives the maximum geographical revenue from the Southern European region.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.